ArticleApplied biochemistry and biotechnology2026
MXene-Based MnZnO Nanocomposites for Enhanced Antibacterial Activity and Cutaneous Wound Healing.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of therapeutic platforms that meet the multifunctional requirements in wound healing is required due to the emergence of antibiotic-resistant bacteria and the need for rapid healing with efficient therapeutic materials. While MXene has proven to be a promising 2D material for biomedical applications because of its superior conductivity, abundant surface functional groups and biocompatibility, its biological performance can be further enhanced by designing nanocomposites. In this study, a novel MnZnO@MXene nanocomposite was synthesized by integrating Mn-doped ZnO nanoparticles with MXene nanosheets to achieve synergistically enhanced antimicrobial activity and wound healing performance. The material was characterized using XRD, FTIR, Raman spectroscopy, UV-Visible spectroscopy, SEM, EDX, elemental mapping, and XPS, confirming its successful formation and structure integrity. In addition to demonstrating potent antibacterial activity against both Gram-positive and Gram-negative bacteria, the MnZnO@MXene nanocomposite showed inhibition zones of 22,19 and 18 mm against Escherichia, Pseudomonas aeruginosa, and Staphylococcus aureus while the standard antibiotic Gentamicin showed zones of inhibition of 16 mm against Escherichia coli, 15 mm against Pseudomonas aeruginosa, and 14 mm against Staphylococcus aureus under similar test conditions. Unlike the previously reported MXene-based wound healing systems, the addition of antibacterial and anti-inflammatory properties of Mn-doped ZnO creates a multifunctional platform for wound management. The results from an in vivo study using an excisional skin wound model showed that wound healing was accelerated (95.19% wound closure at day 10) compared with the negative control (66.76%) and tissue morphology was improved. Furthermore, the carrageenan-induced model of acute paw edema showed significant anti-inflammatory activity by reducing paw thickness from 6.96 mm to 4.39 mm at 24 h, comparable to the standard reference drug. The results indicate that the obtained MnZnO@MXene nanocomposites could serve as a potential platform for antibacterial and wound healing applications.
Indexed as
Identifiers
42446771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.